DSpace logo

Please use this identifier to cite or link to this item: http://dspace.bits-pilani.ac.in:8080/jspui/handle/123456789/13570
Full metadata record
DC FieldValueLanguage
dc.contributor.authorPaul, Atish Tulshiram-
dc.date.accessioned2024-01-01T09:06:02Z-
dc.date.available2024-01-01T09:06:02Z-
dc.date.issued2022-
dc.identifier.urihttps://www.tandfonline.com/doi/full/10.1080/13543776.2021.1954161-
dc.identifier.urihttp://dspace.bits-pilani.ac.in:8080/xmlui/handle/123456789/13570-
dc.description.abstractCurrent health trends indicate that the rate of incidence of obesity has risen considerably. According to the World Health Organization (WHO) report 2017, the issue of obesity has grown to an epidemic proportion, with over 4 million people dying every year. Orlistat, a potent pancreatic lipase (PL) inhibitor for long-term treatment of obesity has been recently reported to cause hepatic and renal toxicities. Hence, there is a need to develop newer, safer and efficacious therapeutics that targets obesity and its associated disorders.en_US
dc.language.isoenen_US
dc.publisherTaylor & Francisen_US
dc.subjectPharmacyen_US
dc.subjectObesityen_US
dc.subjectPlantsen_US
dc.subjectMicro-organismsen_US
dc.subjectExtractsen_US
dc.subjectNatural productsen_US
dc.subjectCombinationen_US
dc.titleMechanistically acting anti-obesity compositions/formulations of natural origin: a patent review (2010-2021)en_US
dc.typeArticleen_US
Appears in Collections:Department of Pharmacy

Files in This Item:
There are no files associated with this item.


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.